Robert Wolff, MD
Ophthalmology · Carson City, NVNPI 1477558195
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,027 of the $11,605 with a category attached, or 69.2%. 24 manufacturers reported payments, led by Carl Zeiss Meditec Cataract Technology Inc. at 28.2% of the total. Reporting peaked in 2021 at $3,719 and has fallen 78.0% since, to $819 in 2025.
Across 176 payments — averaging $65.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec Cataract Technology Inc.$3K
- Alcon$2K
- Glaukos Corporation$2K
- NEW World Medical,inc.$925
- Rxsight Inc$622
- Johnson & Johnson Surgical Vision, Inc.$491
- plus $2K from 18 others
What the payments were for
- Consulting fees$3,40029%
- Speaking & faculty fees$260%
- Travel & lodging$120%
- Food & beverage$8,02769%
- Gifts$1401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec Cataract Technology Inc. | 5 | $3,276 |
| Alcon | 37 | $2,281 |
| Glaukos Corporation | 18 | $1,710 |
| NEW World Medical,inc. | 8 | $925 |
| Rxsight Inc | 12 | $622 |
| Johnson & Johnson Surgical Vision, Inc. | 16 | $491 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 22 | $409 |
| Bausch & Lomb Americas Inc. | 9 | $379 |
| AbbVie(2 entities) | 11 | $280 |
| Ivantis, Inc | 2 | $243 |
| Sight Sciences, Inc. | 7 | $235 |
| Carl Zeiss Meditec, Inc. | 4 | $190 |
| Biotissue Holdings Inc. | 5 | $113 |
| Aerie Pharmaceuticals, Inc. | 2 | $78 |
| Tearlab Corp | 2 | $76 |
| Novartis | 3 | $55 |
| Dompe US, Inc. | 3 | $51 |
| Sun Pharmaceutical Industries Inc. | 2 | $45 |
| Mallinckrodt Enterprises LLC | 2 | $41 |
| Eyepoint US, Inc. | 2 | $39 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Omeros Corporation | 1 | $15 |
| Thea Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$798
- Clearpath$798
- Ahmed Glaucoma Valve$798
- Streamline$798
- Clareon$350
- iDose$295
- iStent inject W$279
- Via360$257
- Centurion$247
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$244
- Hydrus$150
- iDoseTR$133
- iStent Trabecular Micro-Bypass System Model iS3$133
- IACCESS$127
- ORA System VerifEye$122
- iStent Trabecular Micro-Bypass Stent System$122
- iStent inject Trabecular Micro-Bypass Stent System$122
- Photrexa$121
- AcrySof IQ VIVITY IOL$119
- RXSIGHT INJECTOR HANDPIECE$113
How this compares
$11,605 in reported general payments places this provider in the 85th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 304 | $105,946 |
| RestasisCyclosporine | 12 | $9,499 |
| Prednisolone Acetate | 127 | $6,114 |
| Bromfenac Sodium | 14 | $3,132 |
| Latanoprost | 229 | $3,117 |
| Timolol Maleate | 63 | $1,305 |
| Ketorolac Tromethamine | 19 | $745 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $310 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 31 | $303 |
| Ofloxacin | 23 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $409 | $105,946304 claims |
| AbbVieRestasis | $280 | $9,49912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Carson City
- Michael WestaferCarson City$4K
- Ziqiang WuCarson City$3K
- Mehdi VazeenCarson City$2K
- Charlotte WrightCarson City$2K
- Arshad KhananiReno$2M
- Eva LiangLas Vegas$496K
- Rene ZamoraHenderson$216K
- Steven LeibowitzLas Vegas$147K
- Steve ChangReno$75K
- Curtis ManningSparks$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.